C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
A61K 31/7105 - Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
The compositions and methods described herein include methods and agents that inhibit inflammasome signaling in a mammal such as antibodies directed against inflammasome components used alone or in combination with extracellular vesicle uptake inhibitor(s) or other agents. Also described herein are compositions and methods of use thereof for detecting and treating early-stage Alzheimer's disease as well as other inflammatory neurologic conditions.
C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
A61K 39/395 - Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
A61P 11/00 - Drugs for disorders of the respiratory system
A61P 25/00 - Drugs for disorders of the nervous system
A61P 25/14 - Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
A61P 37/06 - Immunosuppressants, e.g. drugs for graft rejection
C07K 16/18 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans
3.
METHOD OF TREATING POLYAMINE IMBALANCE-RELATED DISORDERS
The disclosure provides a method of treating a polyamine imbalance-related disorder. The method comprises administering phenylbutyrate to a subject in need thereof, thereby treating the polyamine imbalance-related disorder.
A61K 31/192 - Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
A61P 43/00 - Drugs for specific purposes, not provided for in groups
C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
4.
ENGINEERED MEGANUCLEASES THAT TARGET HUMAN MITOCHONDRIAL GENOMES
Disclosed herein are recombinant meganucleases engineered to recognize and cleave a recognition sequence present in the human mitochondrial DNA (mtDNA). The disclosure further relates to the use of such recombinant meganucleases in methods for producing genetically-modified eukaryotic cells, and to a population of genetically-modified eukaryotic cells wherein the mtDNA has been having modified or edited.
An array of inflammatory cytokines are useful as a biomarker of traumatic brain injury, including inflammasome proteins. Biomarker cut-off points, ROC, and other characteristics have been determined.
The present disclosure is directed to methods of treating Allan-Herndon-Dudley syndrome comprising administering 3,5-diiodothyropropionic acid (DITPA) to a subject in need thereof, and to administering gene therapy to the subject by introducing normal human MCT8 into the subject's cells in order to increase T3 in the subject's brain.
A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
A61K 31/192 - Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
A61P 25/00 - Drugs for disorders of the nervous system
8.
METHODS AND FORMULATIONS FOR PRENATAL TREATMENT OF ALLAN-HERNDON-DUDLEY SYNDROME
The present disclosure is directed to methods of treating Allan-Herndon-Dudley syndrome comprising administering 3,5-diiodothyropropionic acid (DITPA) to a pregnant mother of a prenatal subject in need thereof, and to pharmaceutical DIPTA formulations for administration to the pregnant mother of a prenatal subject in need thereof.
The present subject matter is directed to methods of treating Allan-Herndon-Dudley syndrome comprising administering 3,5-diiodothyropropionic acid (DITPA) to a subject in need thereof, wherein the DITPA administration reduces triiodothyronine (“T3”) serum levels to normal, increases T3 brain levels to normal, and maintains normal serum levels of thyroxine (T4) and thyroid stimulating hormone (TSH). The subject may be a child or an adult.
C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
C07K 16/40 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against enzymes
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A pharmaceutical composition for use in preventing or treating graft versus host disease (GVHD) in a subject wherein the composition includes intact microvesicles isolated from a biological fluid using polyethylene glycol (PEG) precipitation, wherein administration of the pharmaceutical composition alleviates or prevents one or more symptoms of GVHD in the subject. Also described is a method of preventing or treating graft versus host disease (GVHD) in a subject comprising administering to the subject a pharmaceutical composition comprising intact microvesicles isolated from a biological fluid of an unrelated or related donor using polyethylene glycol (PEG) precipitation wherein one or more symptoms of GVHD comprising weight loss, cutaneous tissue damage, subcutaneous tissue damage, cutaneous inflammation, satellite cell necrosis, truncated lifespan, and/or subcutaneous inflammation are prevented or alleviated in the subject.
Provided herein are small molecule inhibitors of coronavirus attachment and entry, related pharmaceutical compositions, uses, and methods thereof, wherein the compound has a structure of Formula (I):
Provided herein are small molecule inhibitors of coronavirus attachment and entry, related pharmaceutical compositions, uses, and methods thereof, wherein the compound has a structure of Formula (I):
A61K 31/166 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon atom of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
The present invention relates to the fields of medicine, cell biology, molecular biology and genetics. In particular, the present invention provides methods to isolate and purify microvesicles from cell culture supernatants and biological fluids. The present invention also provides pharmaceutical compositions of microvesicles to promote or enhance wound healing, stimulate tis -sue regeneration, remodel scarred tissue, modulate immune reactions, alter neoplastic cell growth and/or mobility, or alter normal cell growth and/or mobility. The present invention also provides compositions of microvesicles to be used as diagnostic reagents, and methods to prepare the compositions of microvesicles.
A61K 35/12 - Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
A61K 8/98 - Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof, of undetermined constitution of animal origin
A61K 35/22 - Urine; Urinary tract, e.g. kidney or bladder; Intraglomerular mesangial cells; Renal mesenchymal cells; Adrenal gland
The present invention provides novel markers of the severity of a central nervous system injury, such as spinal cord injury or traumatic brain injury, in a patient. In particular, protein components of inflammasomes in the cerebrospinal fluid that can be used to assess the severity of central nervous system injury in a patient are disclosed. Methods of using such protein biomarkers to determine a prognosis, direct treatment and rehabilitation efforts, and monitor response to treatment for a patient with a central nervous system injury are also described.
In certain embodiments, double-vision-related vision defects determinations or modifications may be facilitated. In some embodiments, a stimulus may be to be presented at a first time at a position on a first display for a deviating eye of a user (e.g., without a stimulus being presented on a second display of for a reference eye of the user) to cause the deviating eye to fixate on the position on the first display. A deviation measurement for the deviating eye may be determined based on an amount of movement of the deviating eye occurring upon the presentation on the first display for the deviating eye at the first time. In some embodiments, a modification profile associated with the user may be determined based on the deviation measurement, where the modification profile includes one or more modification parameters to be applied to modify an image for the user.
A61B 3/028 - Subjective types, i.e. testing apparatus requiring the active assistance of the patient for determination of refraction, e.g. phoropters
H04N 9/64 - Circuits for processing colour signals
A61B 3/00 - Apparatus for testing the eyes; Instruments for examining the eyes
A61B 3/14 - Arrangements specially adapted for eye photography
A61B 3/113 - Objective types, i.e. instruments for examining the eyes independent of the patients perceptions or reactions for determining or recording eye movement
G06V 20/20 - Scenes; Scene-specific elements in augmented reality scenes
G06V 40/18 - Eye characteristics, e.g. of the iris
G06F 18/214 - Generating training patterns; Bootstrap methods, e.g. bagging or boosting
G06V 10/764 - Arrangements for image or video recognition or understanding using pattern recognition or machine learning using classification, e.g. of video objects
G06V 10/774 - Generating sets of training patterns; Bootstrap methods, e.g. bagging or boosting
Disclosed herein are recombinant meganucleases engineered to recognize and cleave a recognition sequence present in the human mitochondrial DNA (mtDNA). The disclosure further relates to the use of such recombinant meganucleases in methods for producing genetically-modified eukaryotic cells, and to a population of genetically-modified eukaryotic cells wherein the mtDNA has been having modified or edited.
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
A61K 31/198 - Alpha-amino acids, e.g. alanine, edetic acid (EDTA)
A61K 31/352 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
A61K 31/4184 - 1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
A61K 31/4188 - 1,3-Diazoles condensed with heterocyclic ring systems, e.g. biotin, sorbinil
A61K 31/428 - Thiazoles condensed with carbocyclic rings
A61K 31/473 - Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
A61K 31/499 - Spiro-condensed pyrazines or piperazines
A61K 31/502 - Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
A61K 31/517 - Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
A61K 31/7105 - Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
C12N 9/04 - Oxidoreductases (1.), e.g. luciferase acting on CHOH groups as donors, e.g. glucose oxidase, lactate dehydrogenase (1.1)
C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
G01N 33/66 - Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood sugars, e.g. galactose
19.
SYSTEM AND METHOD FOR CONCURRENT ENCRYPTION AND LOSSLESS COMPRESSION OF DATA
The Research Foundation for the State University of New York (USA)
University of Miami (USA)
Stetson University (USA)
Inventor
Arnavut, Ziya
Koc, Basar
Koçak, Hüseyin
Abstract
A system and method for concurrent encryption and lossless compression of data with an algorithm executing on a computer platform. The lossless compression component of the algorithm consists of preprocessing the data with a Burrows-Wheeler transformation followed by an inversion ranking transformation in advance of employing an entropy coder, such as binary arithmetic coder. The frequency vector of the Inversion Ranking transformation is then encrypted and transmitted along with the compressed data with only the frequency vector encrypted. Since the frequency vector is required for decompression, no further encryption of the compressed data is necessary to secure the compressed file.
H03M 7/30 - Compression; Expansion; Suppression of unnecessary data, e.g. redundancy reduction
H03M 7/40 - Conversion to or from variable length codes, e.g. Shannon-Fano code, Huffman code, Morse code
H03M 7/46 - Conversion to or from run-length codes, i.e. by representing the number of consecutive digits, or groups of digits, of the same kind by a code word and a digit indicative of that kind
20.
GAIN-SCHEDULING SYSTEM AND METHOD FOR IMPROVING FAN SPEED CONTROL IN AIR HANDLING UNITS
The Board of Regents of the University of Oklahoma (USA)
University of Miami (USA)
Inventor
Wang, Gang
Song, Li
Wang, Zufen
Hurt, Rodney D.
Abstract
The present disclosure describes a system comprising a gain-scheduling control strategy which improves its nonlinear control performance. A control-oriented model, which does not require numerous physical parameters and extensive test data, has been developed to address the nonlinearity of the fan system. Based on theoretical model and experimental verifications, the issue of an aggressive response with a conventional fixed-gain controller is caused by the fact that the system gain is proportional to the ratio of the duct static pressure to the fan speed. To address the issue, a scheduling function of the measurable duct static pressure and fan speed is included in the conventional fixed-gain controller to compensate for the fan system gain variation. The gain-scheduling control strategy approximately maintains the identical control performance under all operation conditions. The gain-scheduling control strategy can be readily implemented on a processor without intensive computation and additional measurements.
F24F 11/77 - Control systems characterised by their outputs; Constructional details thereof for controlling the supply of treated air, e.g. its pressure for controlling air flow rate or air velocity by controlling the speed of ventilators
The present invention provides compositions and methods for detecting components of the inflammasome in a sample from a subject as markers for brain injuries such as multiple sclerosis, stroke or traumatic brain injury. Methods of using such inflammasome markers to determine prognosis, direct treatment and monitor response to treatment for the subject with a brain injury such as multiple sclerosis, stroke, mild cognitive impairment or traumatic brain injury are also described.
G01N 33/68 - Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
A61K 31/136 - Amines, e.g. amantadine having aromatic rings, e.g. methadone having the amino group directly attached to the aromatic ring, e.g. benzeneamine
A61K 31/137 - Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine
Activation of STimulator of INterferon Genes (STING) triggers cytokine production and facilitates tumor antigen cross-presentation. In an embodiment of the present invention, STING-dependent innate immune signaling pathway activators (STAVs) can be delivered to antigen presenting cells. In various embodiments of the present invention, the STAVs can be delivered in lipid nanoparticle formulations. In various embodiments of the present invention, the range of cancers amenable to STAV therapy can be extended using a non-cell-based nanoparticle strategy that effectively delivers Nano-STAVs into the Tumor Micro Environment (TME) to potently generate anti-tumor cytotoxic T cell activity. The STAV formulations can be introduced into solid tumors present in the mammal. Alternatively, the Nano-STAVs can be introduced through direct inoculation. The lipid nanoparticles stick to the tumor cells and are co-phagocytosed to activate STING in APC's.
A61K 31/711 - Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
The present disclosure relates, in general, to oligonucleotides that stimulate STING (STimulator of Interferon Genes) activity and increase activity of immune cells. The disclosed STING activators (STAVs) are useful in the treatment of cancer and other immune-mediated conditions.
Systems and methods for assessing, monitoring, or theranosing a condition or disorder based on a comparison of limb stability for one or more limbs of a subject from a baseline. The method includes placing two or more inertial measurement sensors on the limbs of the subject, acquiring baseline limb excursion data from the inertial measurement sensors while a patient is performing at least one of a static balance activity and a dynamic balance activity by tracking the relative displacement of the respective two or more inertial measurement sensors; acquiring post-injury limb excursion data after an injury from the inertial measurement sensors while a patient is performing at least one of a static balance activity and a dynamic balance activity; and determining the activity clearance index as a function of a comparison of the baseline limb excursion data compared to the post-injury limb excursion data.
Embodiments of an improved photodynamic therapy device are provided. An example of the device includes an irradiation head having a first end and a surface at a second end, the surface having a radius of curvature. The device also includes a plurality of light sources disposed on the curved surface. The plurality of light sources are configured to emit light having at least one wavelength corresponding approximately to an excitation peak of at least one photosensitizer. The light emitted by the plurality of light sources is focused to a focal point based on the radius of curvature of the surface and a target surface (e.g., a corneal surface of an eye) may be positioned at the focal point for treatment.
Systems and methods for an improved dosimeter for measuring dosage for photodynamic therapy treatment are provided. An example systems includes a dosimeter comprising a variable optical filter system configured to receive a second light, the second light comprising luminescence produced by singlet oxygen and one or more background signal and selectively transmit the luminescence and the one or more background signals as a third light, the variable optical filter system comprises a plurality of optical bandpass filters that are switchable to selectively transmit the luminescence and the one or more background signals. The dosimeter also includes a photoreceiver configured to receive the third light and configured to generate electrical output signals corresponding to the luminescence and the one or more background signals, the electrical output signals being indicative of an amount of the singlet oxygen produced based on activating the photosensitizer.
A61B 5/1455 - Measuring characteristics of blood in vivo, e.g. gas concentration, pH-value using optical sensors, e.g. spectral photometrical oximeters
The disclosure provides a method of predicting the onset of clinical manifestations of amyotrophic lateral sclerosis (ALS) in a human, the method comprising (a) measuring phosphorylated neurofilament heavy chain (pNfH) and/or neurofilament light chain (NfL) levels in a subject, and (b) predicting the onset of ALS, wherein increased levels of pNfH and/or NfL signal the onset of clinical manifestations of ALS.
G01N 33/68 - Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
28.
METHODS AND COMPOSITIONS RELATED TO GUT TRANSIT MEASUREMENT
Disclosed herein are methods and compositions related to determining gut transit time. The composition comprises a blue dye, which can be used to measure transit time from consumption to elimination as a waste product.
Hydrodynamic methods for conformally coating non-uniform size cells and cell clusters with biomaterials for implantation, thus preventing immune rejection or inflammation or autoimmune destruction while preserving cell functionality, are disclosed. Further disclosed are reagents, apparatus, and methods for conformally coating cells and cell clusters with hydrogels that are biocompatible, mechanically and chemically stable and porous, with an appropriate pore cut-off size.
Topical formulations of CoQ10 reduce the rate of tumor growth in an animal subject. In the experiments described herein, CoQ10 was shown to increase the rate of apoptosis in a culture of skin cancer cells but not normal cells. Moreover, treatment of tumor-bearing animals with a topical formulation of CoQ10 was shown to dramatically reduce the rate of tumor growth in the animals.
A61K 9/00 - Medicinal preparations characterised by special physical form
A61K 47/24 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
A61K 36/53 - Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
A61K 31/351 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
A61K 31/122 - Ketones having the oxygen atom directly attached to a ring, e.g. quinones, vitamin K1, anthralin
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
31.
CANNABIDIOL NANODRUG FORMULATIONS AND METHODS FOR USE OF THE SAME
Disclosed herein are topical formulations of cannabidiol, such as nanoparticulate cannabidiol, methods of making such compositions, and their use in treating autoimmune diseases and disorders, e.g., alopecia areata.
G01N 33/50 - Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
The United States Government as Represented by the Department of Veterans Affairs (USA)
Inventor
Mirsaeidi, Mehdi
Zhang, Chongxu
Schally, Andrew V.
Cai, Renzhi
Tian, Runxia
Abstract
The present disclosure is directed to a method of treating an inflammatory disorder, such as sarcoidosis, using a growth hormone-releasing hormone (GHRH) antagonist.
Disclosed herein are Notch transcriptional activation complex kinase (“MACK”) inhibitors, and methods for their use in treating or preventing diseases, such as cancer. The inhibitors described herein include compounds of Formula (Ia) and pharmaceutically acceptable salts thereof: wherein the substituents are as described.
Disclosed herein are Notch transcriptional activation complex kinase (“MACK”) inhibitors, and methods for their use in treating or preventing diseases, such as cancer. The inhibitors described herein include compounds of Formula (Ia) and pharmaceutically acceptable salts thereof: wherein the substituents are as described.
Systems and devices for temporarily disabling an assailant or other target using disabling flashes of light from a light-emitting device. A tactical lighting system also includes protective eyewear that is paired with the light-emitting device and configured to shutter in synchronization with the pattern of disabling light flashes to protect the wearer’s eyes while disabling an assailant or other target. In one embodiment, the tactical lighting system is modular, with each module being functional independently of the other modules.
The disclosure provides a method of forming carbon dots, including admixing carbon powder with sulfuric acid and nitric acid and heating the carbon powder mixture to reflux to oxidize the carbon powder. The method further includes isolating and purifying the carbon dots. The disclosure further provides applications of the carbon dots for diagnostic analysis (such as bone analysis), fibrillation inhibition, and drug delivery.
A microfluidic structure includes a first media channel or well and a second media channel. A removable membrane is provided between the first media channel or well and the second media channel to permit diffusion. One or more plates is used to form the second media channel. A method of creating a microenvironment using the microfluidic structure is also provided.
Ion booster for thrust generation. The invention pertains to electrical propulsion generated by the rapid acceleration of ions between asymmetrical electrodes. The invention is applicable for propulsion generation in atmospheric and space environments.
Various methods and compositions are provided which can be employed to modulate the immune system. Compositions include a fusion protein comprising: (a) a first polypeptide comprising Interleukin-2 (IL-2) or a functional variant or fragment thereof; and (b) a second polypeptide, fused in frame to the first polypeptide, wherein the second polypeptide comprises an extracellular domain of Interleukin-2 Receptor alpha (IL-2Rα) or a functional variant or fragment thereof, and wherein the fusion protein has IL-2 activity. Various methods are provided for modulating the immune response in a subject comprising administering to a subject in need thereof a therapeutically effective amount of the IL-2/IL-2Rα fusion protein disclosed herein.
System for combined intraoperative aberrometry and optical coherence tomography (OCT). In an embodiment, the system comprises an OCT system, an aberrometer, a beam delivery system, and a beam splitter. The beam delivery system is configured to output a beam towards a target, wherein the beam has an outward path to the target and a return path after being reflected by the target. The beam splitter is positioned in the return path of the beam and configured to split the return path into a first path to the OCT system and a second path to the aberrometer. Thus, the OCT system and aberrometer can share a single beam delivery system.
A device, kit, and method for aspirating graft tissue and delivering the graft tissue to a target delivery site. An injector comprises a cylinder and a plunger that is both linearly and rotatably advanceable and retractable within the cylinder. A kit comprises an injector, a cartridge, and a cartridge coupling element that connects the cartridge to the injector. The kit may also include a container that is configured to retain a cartridge and to facilitate connection between the injector and the cartridge. The container includes at least one fluid barrier that prevents spillage of storage solution from the container when the injector is at least partially inserted into the well of the container.
A61M 1/00 - Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
42.
Methods for Identifying Modulators of G Protein-Coupled Receptors
The disclosure relates to a plurality of cells, compositions and methods for identifying modulators of a target protein. The cells, compositions and methods comprise a (i) a target domain gene (ii) an intracellular chimeric G-protein alpha subunit comprising an endogenous G-protein alpha subunit with a humanized C-terminus; and (iii) an inducible reporter, wherein the expression of the reporter is dependent on the activation of the target domain encoded by target domain gene, and wherein the target domain gene comprises a barcode. The disclosure further relates to a host cell comprising a plurality of exogenous landing pads integrated in the host cell's genome, wherein each exogenous landing pad is integrated at a safe harbor genome loci in the host cell's genome.
Described herein is a method for detecting the presence of circulating extracellular vesicles in a subject. The method comprises contacting a biological sample from the subject with an antibody mimetic that specifically binds to a cell surface marker on the vesicles, wherein the antibody mimetic is coupled to a detectable label; and detecting presence of extracellular vesicles in the sample by detecting the presence of the detectable label coupled to the antibody mimetic bound to the vesicles.
A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
This document provides novel compositions and methods utilizing immunomodulating agents that can stimulate or indirectly augment the immune system, or can have an immunosuppressive effect. TNFR25 agonists disclosed herein have an anti-inflammatory and healing effect. They can be used, e.g., to treat disease caused by asthma and chronic inflammation, such as inflammatory bowel diseases including ulcerative colitis and Crohn's Disease. TNFR25 antagonists disclosed herein can inhibit CD8 T cell-mediated cellular immune responses and can, for example, mitigate organ or tissue rejection following a tissue transplantation. TNFR25 agonists disclosed herein represent biological response modifiers that alter the interaction between the body's cellular immune defenses and cancer cells to boost, direct, or restore the body's ability to fight the cancer when given with tumor vaccines. TNFR25 specific immunotoxins disclosed herein are also capable of increasing the effectiveness of a chemotherapeutic regimen by depleting a cancer patient of naturally occurring immunosuppressive cells.
A61K 38/17 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from humans
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
A61K 35/13 - Tumour cells, irrespective of tissue of origin
A61K 39/00 - Medicinal preparations containing antigens or antibodies
A61K 39/395 - Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
This disclosure relates to systems, compounds and methods for stem cell delivery. More specifically, the disclosure relates a system for promoting tissue regeneration, the system comprising a plurality of stem cells coated with at least one or a plurality of dendrimer nanocarriers that specifically bind to an adhesion molecule. Additionally, the disclosure relates to methods for delivering stem cells to damaged or diseased tissue for stem cell regeneration of the tissue.
A61K 35/28 - Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
Ocular photosensitivity analyzer. In an embodiment, a programmable light source, comprising a plurality of multi-spectra light modules, is configured to emit light according to a lighting condition. For one or a plurality of iterations, the programmable light source is activated to emit the light according to the lighting condition, and collect a response, by a subject, to the emitted light via a sensing system comprising one or more sensors. Between iterations, the programmable light source may be reconfigured based on the response to determine a visual photosensitivity threshold of the subject.
This disclosure relates generally to compositions of carbon dots, doxorubicin, and transferrin and methods for use of the same in the treatment of DLBCL tumors.
A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
A61K 31/439 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
A61K 31/573 - Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
49.
ANTI-SECRETOGRANIN III (SCG3) ANTIBODIES AND USES THEREOF
Antibodies specific for secretogranin III (Scg3) are disclosed. Methods of using the antibodies, antigen-binding fragments thereof, or pharmaceutical compositions comprising the same in the treatment of diseases such as diabetic retinopathy, neovascular age-related macular degeneration, retinopathy of prematurity, and cancer, are also disclosed.
C12Q 1/70 - Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
C12Q 1/6848 - Nucleic acid amplification reactions characterised by the means for preventing contamination or increasing the specificity or sensitivity of an amplification reaction
B01L 3/00 - Containers or dishes for laboratory use, e.g. laboratory glassware; Droppers
51.
ADDITIVE MANUFACTURING OF COMPOSITES WITH SHORT-FIBER REINFORCEMENT
Additive manufacturing of composites with short-fiber reinforcement. In an embodiment, an extrusion channel is supplied with a composite ink comprising short fibers, and the composite ink is extruded out of a material outlet of the extrusion channel, while vibrating the extrusion channel and the material outlet by one or more vibration motors along one or more vibration axes, to fabricate a three-dimensional composite structure. The short fibers may comprise milled carbon fibers having an average length of 50 μm or less and an average aspect ratio of 4.5 or less, and the composite ink may comprise a high fiber volume ratio (e.g., 27+%). Despite analytical models that predict otherwise, the composite structures, resulting from disclosed embodiments, have enhanced strength.
B33Y 30/00 - ADDITIVE MANUFACTURING, i.e. MANUFACTURING OF THREE-DIMENSIONAL [3D] OBJECTS BY ADDITIVE DEPOSITION, ADDITIVE AGGLOMERATION OR ADDITIVE LAYERING, e.g. BY 3D PRINTING, STEREOLITHOGRAPHY OR SELECTIVE LASER SINTERING - Details thereof or accessories therefor
Quantification of symmetry and repeatability in limb motion for treating abnormal motion patterns. In the context of gait analysis, gait data may be acquired as signals from inertial sensors (e.g., gryoscopes). Each signal represents an angular velocity of a lower limb segment of a subject during ambulation. Each signal may be segmented into stride signals, and a gait metric may be calculated based on the stride signals. The gait metric may comprise a symmetry metric that represents a similarity of the stride signals across two signals acquired for at least one pair of contralateral limb segments. Additionally or alternatively, the gait metric may comprise a repeatability metric that represents a similarity of the stride signals within a signal. In other embodiments, other types of sensors may be used and/or motion data may be acquired and metrics calculated for other types of motions and/or for upper limb segments.
Artificial intelligence for evaluating patient distress using facial emotion recognition. In an embodiment, an artificial intelligence model is applied to facial image(s) of a patient to classify each facial image into one of a plurality of emotional states based on a facial expression in the facial image. A determination may be made as to whether or not to alert a healthcare provider based on the emotional state(s) into which the facial image(s) were classified. If a determination is made to alert a healthcare provider, a notification may be transmitted to the healthcare provider.
G16H 40/20 - ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the management or administration of healthcare resources or facilities, e.g. managing hospital staff or surgery rooms
G16H 30/00 - ICT specially adapted for the handling or processing of medical images
G06V 40/16 - Human faces, e.g. facial parts, sketches or expressions
G06V 10/82 - Arrangements for image or video recognition or understanding using pattern recognition or machine learning using neural networks
Device for arterial puncture assistance. In an embodiment, the device comprises an upper component, lower component, and coupling mechanism that couples the lower component to the upper component. The upper component may comprise a platform configured to support a syringe. The lower component may comprise one or more finger holes, wherein each of the one or more finger holes is configured to receive a human finger therethrough, so as to enable contemporaneous stabilization of the lower component on the human finger and palpation of an arterial pulse by the human finger during an arterial puncture.
A system for electrohydromodulation of wastewater. In an embodiment, the system comprises an anode in contact with at least one anodic chamber and a cathode in contact with a cathodic chamber. Each anodic chamber and the cathodic chamber are configured to receive a flow of wastewater. A first multivalent cation exchange membrane, between each anodic chamber and the cathodic chamber, allows multivalent cations to pass therethrough while preventing monovalent ions to pass therethrough. A power source is electrically coupled to each anode and the cathode, and is configured to apply a voltage across wastewater in the anodic chamber and the cathodic chamber, to thereby cause multivalent cations in the wastewater to pass through the multivalent cation exchange membrane.
A steerable guide. In an embodiment, the steerable guide comprises a needle, a shaft, a spring housing, and a translational screw. The needle comprises a wire tube and a wire configured to curve the needle when retracted relative to the wire tube. The wire tube is connected to the distal end of the shaft, and the wire is connected to the distal end of the spring housing. The screw extends into a cavity within the shaft, and is configured to move along a longitudinal axis. A spring is positioned within the cavity, between the proximal end of the spring housing and the distal end of the screw. Thus, when the screw moves in the proximal direction while a position of the spring housing is fixed by the wire, the spring is compressed between the proximal end of the spring housing and the distal end of the translational screw.
A61B 90/11 - Instruments, implements or accessories specially adapted for surgery or diagnosis and not covered by any of the groups , e.g. for luxation treatment or for protecting wound edges for stereotaxic surgery, e.g. frame-based stereotaxis with guides for needles or instruments, e.g. arcuate slides or ball joints
A61B 18/22 - Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by applying electromagnetic radiation, e.g. microwaves using laser the beam being directed along or through a flexible conduit, e.g. an optical fibre; Hand-pieces therefor
A61B 18/00 - Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
A61M 25/01 - Introducing, guiding, advancing, emplacing or holding catheters
A61M 25/06 - Body-piercing guide needles or the like
Systems and devices for temporarily disabling an assailant or other target using disabling flashes of light from a light-emitting device. A tactical lighting system also includes protective eyewear that is paired with the light-emitting device and configured to shutter in synchronization with the pattern of disabling light flashes to protect the wearer's eyes while disabling an assailant or other target.
Disclosed herein are inhibitors of the Notch transcriptional activation complex, and methods for their use in treating or preventing diseases, such as cancer. The inhibitors described herein can include compounds of Formula (I) and pharmaceutically acceptable salts thereof: Formula (I), wherein the substituents are as described.
C07D 417/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 403/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
The invention relates to a vector and/or vaccine that can be used for therapeutic and preventive purposes. The virus is based on vesicular stomatitis virus (VSV) with a substituted VSV G (glycoprotein) for HTLV-1 G, referred to as gp62. The vector and/or vaccine further comprise a fusion protein comprising HTLV-1 regulatory proteins (HBZ and TAX) together to make a fusion product (HBZ-TAX) and mutated versions thereof. The vector and/or vaccine do not impede innate immune signaling and generate neutralizing antibodies and CTLs to gp62, HBZ, and TAX.
A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
A61K 31/704 - Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin, digitoxin
A61K 31/711 - Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
A61K 31/7105 - Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
The compositions and methods described herein include methods and agents that inhibit inflammasome signaling in a mammal such as antibodies directed against inflammasome components used alone or in combination with extracellular vesicle uptake inhibitor(s) or other agents. Also described herein are compositions and methods of use thereof for treating viral-associated lung inflammation, for example lung inflammation associated with viral infections such as SARS-CoV-2.
A61P 11/00 - Drugs for disorders of the respiratory system
C07K 16/18 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans
C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
A61P 25/00 - Drugs for disorders of the nervous system
A61K 39/00 - Medicinal preparations containing antigens or antibodies
A61K 39/395 - Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
A system for ophthalmic imaging comprising an ophthalmic device configured to obtain stereoscopic images of an eye of a patient and to transmit the images in real-time to a display device via a network for viewing by practitioners. The ophthalmic device comprises at least an optic assembly, a processing assembly, a slit assembly, such as a slit lamp, and a positioning assembly. Control devices structured to control the ophthalmic device over the network, such as the world wide web, can be disposed at a plurality of locations, and may be remote from the ophthalmic device while providing real time control of the parameters of the ophthalmic device by the practitioner(s) associated therewith.
A lateral flow assay device for testing a biological sample includes housing, a sample receiving pad, a conjugate test pad, and a nitrocellulose membrane. The sample receiving pad and conjugate test pad, as well as the nitrocellulose membrane, are enclosed within an interior portion of the housing. The sample receiving pad is in fluid communication with an opening defined in an outer surface of the housing for receiving the biological sample. At least a portion of the conjugate test pad is in contact with the sample receiving pad and is configured to test the biological sample. At least one window is defined in the outer surface of the housing adjacent the conjugate test pads such that the results of the test performed on the conjugate test pads are visible from outside of the housing.
In some embodiments, initial feedback indicating threshold characteristics (under which a user sees initial stimuli presented on a user interface) may be provided to a prediction model, and a set of predicted characteristics (for a set of locations of the user interface) and a set of confidence scores associated with the set of locations may be obtained via the prediction model. Based on the set of confidence scores, one or more locations may be selected to be tested during a visual test presentation. As an example, the locations may be selected over one or more other locations of the set of locations based on the set of confidence scores. Based on predicted characteristics associated with the selected locations, stimuli may be presented at the selected locations during the visual test presentation. Visual defect information for the user may be generated based on feedback from the visual test presentation.
A61B 3/024 - Subjective types, i.e. testing apparatus requiring the active assistance of the patient for determining the visual field, e.g. perimeter types
G16H 50/30 - ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for individual health risk assessment
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
A61B 3/028 - Subjective types, i.e. testing apparatus requiring the active assistance of the patient for determination of refraction, e.g. phoropters
In some embodiments, initial feedback indicating threshold characteristics (under which a user sees initial stimuli presented on a user interface) may be provided to a prediction model, and a set of predicted characteristics (for a set of locations of the user interface) and a set of confidence scores associated with the set of locations may be obtained via the prediction model. Based on the set of confidence scores, one or more locations may be selected to be tested during a visual test presentation. As an example, the locations may be selected over one or more other locations of the set of locations based on the set of confidence scores. Based on predicted characteristics associated with the selected locations, stimuli may be presented at the selected locations during the visual test presentation. Visual defect information for the user may be generated based on feedback from the visual test presentation.
A61B 3/024 - Subjective types, i.e. testing apparatus requiring the active assistance of the patient for determining the visual field, e.g. perimeter types
G16H 50/30 - ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for individual health risk assessment
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
A61B 3/028 - Subjective types, i.e. testing apparatus requiring the active assistance of the patient for determination of refraction, e.g. phoropters
A method is disclosed for improving accuracy of visual field testing in head-mounted displays. The method includes retrieving a visual field testing pattern for a head-mounted display, the visual field testing pattern including stimuli displayed at respective locations in a visual field of the head-mounted display. The visual field testing pattern is generated on the head-mounted display. Data is retrieved from a tilt sensor, located at the head-mounted display, for detecting degrees of head tilt of a user wearing the head-mounted display and the degree of head tilt is determined. A comparison is made between the degree of head tilt of the user to a first threshold degree. In response to the degree of head tilt of the user meeting or exceeding the first threshold degree, a recommendation to the user is generated for display on the head-mounted display.
A61B 3/024 - Subjective types, i.e. testing apparatus requiring the active assistance of the patient for determining the visual field, e.g. perimeter types
G09G 5/38 - Control arrangements or circuits for visual indicators common to cathode-ray tube indicators and other visual indicators characterised by the display of individual graphic patterns using a bit-mapped memory with means for controlling the display position
A61B 3/032 - Devices for presenting test symbols or characters, e.g. test chart projectors
A61B 5/11 - Measuring movement of the entire body or parts thereof, e.g. head or hand tremor or mobility of a limb
A61B 3/00 - Apparatus for testing the eyes; Instruments for examining the eyes
69.
VISION TESTING VIA PREDICTION-BASED SETTING OF INITIAL STIMULI CHARACTERISTICS FOR USER INTERFACE LOCATIONS
Methods and systems for dynamically determining stimuli characteristics for vision defect determination during a vision test. The methods and systems convert the feedback received from the binary suprathreshold test into a feature input that is provided to a prediction model. The prediction model may be trained to predict non-binary characteristics for sets of locations and confidence scores associated with the sets of locations based on feedback indicating binary characteristics under which users see one or more stimuli presented on user interfaces.
A61B 3/024 - Subjective types, i.e. testing apparatus requiring the active assistance of the patient for determining the visual field, e.g. perimeter types
G16H 50/30 - ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for individual health risk assessment
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
A61B 3/028 - Subjective types, i.e. testing apparatus requiring the active assistance of the patient for determination of refraction, e.g. phoropters
A method is disclosed for improving accuracy of visual field testing in head-mounted displays. The method includes retrieving a visual field testing pattern for a head-mounted display, the visual field testing pattern including icons displayed at respective locations in a visual field of the head-mounted display. The visual field testing pattern is generated on the head-mounted display. Data is retrieved from a tilt sensor, located at the head-mounted display, for detecting degrees of head tilt of a user wearing the head-mounted display and the degree of head tilt is determined. A comparison is made between the degree of head tilt of the user to a first threshold degree. In response to the degree of head tilt of the user meeting or exceeding the first threshold degree, a recommendation to the user is generated for display on the head-mounted display.
A61B 3/024 - Subjective types, i.e. testing apparatus requiring the active assistance of the patient for determining the visual field, e.g. perimeter types
G09G 5/38 - Control arrangements or circuits for visual indicators common to cathode-ray tube indicators and other visual indicators characterised by the display of individual graphic patterns using a bit-mapped memory with means for controlling the display position
A61B 3/032 - Devices for presenting test symbols or characters, e.g. test chart projectors
A61B 5/11 - Measuring movement of the entire body or parts thereof, e.g. head or hand tremor or mobility of a limb
A61B 3/00 - Apparatus for testing the eyes; Instruments for examining the eyes
Some systems and methods disclosed herein facilitate calibration of a head-mounted display while a visual test is performed. One mechanism of facilitating calibration involves detecting, as a visual test is being performed, that the user's eyes moved in the direction of a displayed stimulus but have not stopped at the point of where the stimulus is displayed, and instead stopped at a different point (e.g., a threshold distance away from the stimulus). Based on that detection, the system may determine that the user has seen the stimulus and that calibration of the sensors is needed. The system may then record that the user has seen the stimulus and perform sensor calibration before displaying the next stimulus.
A61B 3/024 - Subjective types, i.e. testing apparatus requiring the active assistance of the patient for determining the visual field, e.g. perimeter types
G09G 5/38 - Control arrangements or circuits for visual indicators common to cathode-ray tube indicators and other visual indicators characterised by the display of individual graphic patterns using a bit-mapped memory with means for controlling the display position
A61B 3/032 - Devices for presenting test symbols or characters, e.g. test chart projectors
A61B 5/11 - Measuring movement of the entire body or parts thereof, e.g. head or hand tremor or mobility of a limb
A61B 3/00 - Apparatus for testing the eyes; Instruments for examining the eyes
The present disclosure relates to a method of treating sensorineural deafness. The disclosure provides a method of treating sensorineural deafness in a mammalian subject (e.g., human) in need thereof. The method comprises administering to a subject having a mutation in a CLDN9 gene a composition that comprises a polynucleotide that encodes a CLDN9 peptide, a CLDN9 peptide, an agent that blocks expression of a mutant CLDN9 gene, an agent that corrects the mutation in the CLDN9 gene.
A61K 38/17 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from humans
A61K 31/7088 - Compounds having three or more nucleosides or nucleotides
A61K 31/7105 - Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
Systems, methods, and computer readable media for determining cognitive impairment (CI) in patients are provided herein. Various regional structural-functional parameters of the retina can serve as biomarkers for the detection of CI. The method can include forming a database including a quantification of retinal structure and retinal function of a plurality of eyes associated with a plurality of patients, providing a baseline cognitive impairment (CI) reference. The method can include determining a measure of functionality of neurons in the retina based on an electroretinogram (ERG) of a patient. The method can include determining a structural measure of the first retina based on a generalized dimension spectrum and singularity spectrum of the skeletonized retinal image, and a lacunarity parameter of the skeletonized retinal image. The method can include determining a level of cognitive impairment based on the structural and functional measures.
A61B 5/00 - Measuring for diagnostic purposes ; Identification of persons
A61B 3/12 - Objective types, i.e. instruments for examining the eyes independent of the patients perceptions or reactions for looking at the eye fundus, e.g. ophthalmoscopes
A61B 5/398 - Electrooculography [EOG], e.g. detecting nystagmus; Electroretinography [ERG]
74.
COMPOSITIONS AND METHODS OF TREATMENT USING MICROVESICLES FROM BONE MARROW-DERIVED MESENCHYMAL STEM CELLS
Methods and systems for retrofitting an ophthalmic device to obtain stereoscopic images of an eye of a patient and to transmit the images in real-time to a display device via a network for viewing by practitioners. The ophthalmic device may comprise at least an optic assembly, a processing assembly, a slit assembly, such as a slit lamp, and a positioning assembly. Control devices structured to control the ophthalmic device over the network, such as the world wide web, can be disposed at a plurality of locations, and may be remote from the ophthalmic device while providing real time control of the parameters of the ophthalmic device by the practitioner(s) associated therewith.
A61B 3/00 - Apparatus for testing the eyes; Instruments for examining the eyes
G16H 40/67 - ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices for remote operation
76.
TARGETING OF MAKAP-PDE4D3 COMPLEXES IN NEURODEGENERATIVE DISEASE
The Board of Trustees of the Leland Stanford Junior University (USA)
The University of Miami (USA)
Inventor
Kapiloff, Michael S.
Goldberg, Jeffrey L.
Abstract
Nervous system trauma and neurodegeneration including in optic neuropathies are treated by administration of an effective dose of a PDE4D3 displacing agent to promote neurite extension, neuroprotection and recovery. In some embodiments the neurons are optic neurons, including without limitation retinal ganglion cells (RGCs). A cAMP signaling compartment restricted by mAKAPα-anchored PDE4D3 directly regulates neuronal phenotype, and can be molecularly manipulated with therapeutic effect.
C07K 14/47 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from humans from vertebrates from mammals
Systems and methods provide a parallelized deep learning approach to spectral fitting for magnetic resonance spectroscopy data enabling accurate and rapid spectral fitting and determination of metabolite measurements using a conventional computer. The method may include processing multi-spectra magnetic resonance (MR) spectroscopy data of a region of interest through a series of neural networks. The method may include determining baseline components of each spectrum using a first neural network of the series, generating baseline-corrected components for each spectrum using the baseline components; and determining one or more peak components of each spectrum using a second neural network of the series and the baseline-corrected components. The method may further include determining one or more metabolite measurements of the one or more metabolites in the region of interest using the one or more peak components.
G01R 33/485 - NMR imaging systems with selection of signal or spectra from particular regions of the volume, e.g. in vivo spectroscopy based on chemical shift information
The Board of Trustees of the Leland Stanford Junior University (USA)
Inventor
Kapiloff, Michael S.
Li, Jinliang
Abstract
The present invention provides a method of treating heart failure with reduced ejection fraction, by administering to a patient at risk of such damage, a pharmaceutically effective amount of a composition which inhibits the anchoring of PP2A to mAKAPβ. This composition is preferably in the form of a viral based gene therapy vector that encodes a fragment of mAKAPβ to which PP2A binds.
A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
In certain embodiments, double-vision-related vision defects determinations or modifications may be facilitated. In some embodiments, a stimulus may be to be presented at a first time at a position on a first display for a deviating eye of a user (e.g., without a stimulus being presented on a second display of for a reference eye of the user) to cause the deviating eye to fixate on the position on the first display. A deviation measurement for the deviating eye may be determined based on an amount of movement of the deviating eye occurring upon the presentation on the first display for the deviating eye at the first time. In some embodiments, a modification profile associated with the user may be determined based on the deviation measurement, where the modification profile includes one or more modification parameters to be applied to modify an image for the user.
A61B 3/028 - Subjective types, i.e. testing apparatus requiring the active assistance of the patient for determination of refraction, e.g. phoropters
H04N 9/64 - Circuits for processing colour signals
A61B 3/00 - Apparatus for testing the eyes; Instruments for examining the eyes
A61B 3/14 - Arrangements specially adapted for eye photography
A61B 3/113 - Objective types, i.e. instruments for examining the eyes independent of the patients perceptions or reactions for determining or recording eye movement
G06V 20/20 - Scenes; Scene-specific elements in augmented reality scenes
G06V 40/18 - Eye characteristics, e.g. of the iris
G06F 18/214 - Generating training patterns; Bootstrap methods, e.g. bagging or boosting
G06V 10/764 - Arrangements for image or video recognition or understanding using pattern recognition or machine learning using classification, e.g. of video objects
G06V 10/774 - Generating sets of training patterns; Bootstrap methods, e.g. bagging or boosting
The present disclosure is directed to methods for determining responsiveness to cell therapy in a subject suffering from a cardiovascular disorder (e.g., cardiomyopathy) and methods of treating subjects suffering from a cardiovascular disorder.
C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
A61K 35/28 - Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
81.
Compositions and Production of Recombinant AAV Viral Vectors Capable of Glycoengineering In Vivo
The disclosure provides an expression vector (e.g., AAV vector) comprising a nucleic acid sequence encoding (1) the heavy and/or light chain of an antibody and (2) one or more shRNA sequences targeting fucosyltransferase-8 (FUT8).
THE UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS (USA)
UNIVERSITY OF MIAMI (USA)
Inventor
Jackson, Robert M.
Schally, Andrew V.
Cai, Renzhi
Cai, Xianyang Zhang
Wang, Haibo
Sha, Wei
Abstract
Described herein are compositions and methods for treating pulmonary fibrosis and cancer. The compositions include growth hormone releasing hormone peptides. The methods include reducing lung inflammation, lung scarring, reducing expression of T cell receptor complex genes as well as inhibiting tumor growth.
The present disclosure relates, in general, to oligonucleotides that stimulate STING (STimulator of INterferon Genes) activity and increase activity of immune cells. The disclosed STING activators (STAVs) are useful in the treatment of cancer and other immune-mediated conditions.
C07H 21/04 - Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
A61K 39/00 - Medicinal preparations containing antigens or antibodies
An ingestible capsule device collects fluid aspirates from locations within the body, locations such as the small intestine, and retains the fluid aspirates free from contamination as the capsule device is expelled from the body. The device allows for microbial and metabolomics analysis for a variety of gastrointestinal, allergic, endocrinologic, and oncologic diseases. In some examples, the capsule device is a multi-stroke device that includes a capsule shell and two reservoirs located within the shell. Check valves work in conjunction with a vacuum pressure pumping mechanism to control fluid movement from one reservoir to another, where one of the reservoirs may be expandable and permeable to some fluids. In other examples, the capsule device employs a peristaltic pump fluid control with the capsule device, and a single semi-permeable bladder stores collected fluid aspirate.
A61B 10/00 - Other methods or instruments for diagnosis, e.g. for vaccination diagnosis; Sex determination; Ovulation-period determination; Throat striking implements
A61B 5/145 - Measuring characteristics of blood in vivo, e.g. gas concentration, pH-value
Devices, systems, and methods for remotely and, optionally, continuously, reading a temperature of an object, such as a human. In one embodiment, a temperature sensor patch comprises: a sensor circuit, the sensor circuit including: a radiofrequency identification (RFID) chip; and an antenna; and a layer of base material, the sensor circuit being in the layer of material and the layer of base material being configured to permit a signal transfer between the sensor circuit and a surrounding environment.
G01N 33/68 - Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
88.
Vectors and vaccine cells for immunity against Zika virus
The present invention provides an expression vector, host cells, methods and kits for the treatment or prevention of a flavivirus infection in a subject.
The compositions and methods described herein include agents that inhibit inflammasome signaling in the mammal such as antibodies directed against inflammasome components used alone or in combination with extracellular vesicle uptake inhibitor(s). Also described herein are compositions and methods of use thereof for treating inflammasome related diseases or conditions.
C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
C07K 16/18 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans
A61P 11/00 - Drugs for disorders of the respiratory system
A61P 25/00 - Drugs for disorders of the nervous system
A61K 39/395 - Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
A61P 25/14 - Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
A61P 37/06 - Immunosuppressants, e.g. drugs for graft rejection
Disclosed herein is a method of treating or preventing renal disease in a subject suffering from Alport Syndrome, as well a method of treating or preventing chronic kidney disease. The method comprises administering to a subject in need thereof an effective amount of human apolipoprotein M.
A device and method for preserving corneal graft tissue. In one embodiment, a device for preserving corneal graft tissue comprises: a first chamber; a second chamber; and a corneal graft tissue suspension assembly that is configured to retain and suspend the corneal graft tissue between the first chamber and the second chamber, the first chamber being fluidly isolated from the second chamber when the corneal graft tissue is graft tissue is retained and suspended within the corneal graft tissue suspension assembly. In one embodiment, a method includes filling a first chamber of a device with a first preservation medium and filling a second chamber of the device with a second preservation medium different than or the same as the first, a corneal graft tissue being located between the first and second chambers.
A61F 2/00 - Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
92.
Breath analysis methodology for medical diagnostics
Systems and methods for diagnosing a condition in an individual by analyzing the individual's breath are provided. Sensors may be configured to capture data associated with the breath of an individual. The data captured by the sensors may include a change in resistance measurements recorded by solid-state sensors when the sensors are exposed to the individual's breath at several different temperatures. This captured data may be analyzed to identify one or more volatile organic compound (VOC) biomarkers in the individual's breath. Based on the identified VOC biomarkers, a condition associated with the individual may be determined. For example, a medical condition, or a condition of drowsiness or fatigue associated with the individual may be determined based on the VOC biomarkers in the individual's breath. In some examples, the sensors may be positioned inside a vehicle for determination of condition associated with a driver of the vehicle.
A61B 5/08 - Measuring devices for evaluating the respiratory organs
G16H 40/63 - ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices for local operation
A61B 5/18 - Devices for psychotechnics; Testing reaction times for vehicle drivers
A61B 5/00 - Measuring for diagnostic purposes ; Identification of persons
G01N 33/497 - Physical analysis of biological material of gaseous biological material, e.g. breath
93.
PERSONALIZED DEVICE TO AUTOMATICALLY DETECT AND REDUCE MUSCLE SPASMS WITH VIBRATION
A61H 23/02 - Percussion or vibration massage, e.g. using supersonic vibration; Suction-vibration massage; Massage with moving diaphragms with electric or magnetic drive
94.
Methods of Treating Renal Disease Associated With Chronic Kidney Disease Such as Alport Syndrome
Disclosed herein is a method of treating renal disease in a subject suffering from Alport Syndrome or chronic kidney disease comprising administering ezetimibe (optionally in combination with ramipril) to the subject in an amount effective to treat the renal disease in the subject.
A61K 31/397 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
A61P 13/12 - Drugs for disorders of the urinary system of the kidneys
A61K 31/403 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
95.
Vision testing via prediction-based setting of an initial stimuli characteristic for a user interface location
In some embodiments, initial feedback indicating threshold characteristics (under which a user sees initial stimuli presented on a user interface) may be provided to a prediction model, and a set of predicted characteristics (for a set of locations of the user interface) and a set of confidence scores associated with the set of locations may be obtained via the prediction model. Based on the set of confidence scores, one or more locations may be selected to be tested during a visual test presentation. As an example, the locations may be selected over one or more other locations of the set of locations based on the set of confidence scores. Based on predicted characteristics associated with the selected locations, stimuli may be presented at the selected locations during the visual test presentation. Visual defect information for the user may be generated based on feedback from the visual test presentation.
A61B 3/024 - Subjective types, i.e. testing apparatus requiring the active assistance of the patient for determining the visual field, e.g. perimeter types
G16H 50/30 - ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for individual health risk assessment
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
A61B 3/028 - Subjective types, i.e. testing apparatus requiring the active assistance of the patient for determination of refraction, e.g. phoropters
Compositions comprising TL1A-Ig fusion proteins and methods of their use, e.g., for the treatment of diseases and disorders associated with antigen-specific immune responses, are described. Also described are combination therapies that include the administration of a TNFRSF25 agonist and an interleukin (e.g., IL-2) and/or an mTOR inhibitor (e.g., rapamycin).
A61K 31/7088 - Compounds having three or more nucleosides or nucleotides
A61K 31/436 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
97.
Kinase inhibitors for the treatment of central and peripheral nervous system disorders
Provided herein are compounds of the general Formula (I) which act as kinase inhibitors, e.g. ROCK, S6K, and/or PKC inhibitors, and are useful in neurite growth and axonal growth.
C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
C07D 403/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
C12N 15/115 - Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith
C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
A61P 37/06 - Immunosuppressants, e.g. drugs for graft rejection
A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
G01N 33/50 - Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
G01N 33/566 - Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagent
A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
The invention provides a method of treating or preventing pain in a subject in need thereof. The method comprising administering to the subject an expression vector comprising a nucleic acid sequence encoding carbonic anhydrase (10) or carbonic anhydrase (11) such that the nucleic acid is expressed to produce carbonic anhydrase (10) or carbonic anhydrase (11). Alternatively, the method comprising administering to the subject an expression vector comprising a nucleic acid sequence encoding a carbonic anhydrase (8) fragment such that the nucleic acid is expressed to produce the carbonic anhydrase (8) fragment.
A method is disclosed for improving accuracy of visual field testing in head-mounted displays. The method includes retrieving a visual field testing pattern for a head-mounted display, the visual field testing pattern including icons displayed at respective locations in a visual field of the head-mounted display. The visual field testing pattern is generated on the head-mounted display. Data is retrieved from a tilt sensor, located at the head-mounted display, for detecting degrees of head tilt of a user wearing the head-mounted display and the degree of head tilt is determined. A comparison is made between the degree of head tilt of the user to a first threshold degree. In response to the degree of head tilt of the user meeting or exceeding the first threshold degree, a recommendation to the user is generated for display on the head-mounted display.
A61B 5/11 - Measuring movement of the entire body or parts thereof, e.g. head or hand tremor or mobility of a limb
A61B 3/024 - Subjective types, i.e. testing apparatus requiring the active assistance of the patient for determining the visual field, e.g. perimeter types
G09G 5/38 - Control arrangements or circuits for visual indicators common to cathode-ray tube indicators and other visual indicators characterised by the display of individual graphic patterns using a bit-mapped memory with means for controlling the display position
A61B 3/032 - Devices for presenting test symbols or characters, e.g. test chart projectors
A61B 3/00 - Apparatus for testing the eyes; Instruments for examining the eyes